Bristol entecavir review
FDA's Antiviral Drugs Advisory Committee will consider Bristol-Myers Squibb's entecavir for the treatment of chronic hepatitis B infection on March 11. Bristol announced its submission of entecavir Oct. 4, 2004; the application is receiving a six-month priority review. The meeting will be held at the Hilton in Gaithersburg, Md. at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.